Journal profile · Pharmacology & Pharmacy
Expert Opinion on Therapeutic Targets
ISSN 1472-8222 · eISSN 1744-7631 · Taylor and Francis Ltd. · ENGLAND · Monthly · Founded 2001
Expert Opinion on Therapeutic Targets: CAS Zone 2 · Medicine (2025 upgraded edition); impact factor 5.27; hybrid open access; median 94 days to acceptance (108 articles, last 24 months); community-reported acceptance: moderate; 74 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Expert Opinion on Therapeutic Targets is published by Taylor and Francis Ltd. and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Cytokine Signaling Pathways and Interactions, MicroRNA in disease regulation and PI3K/AKT/mTOR signaling in cancer, together about 15.1% of its articles. Its main subfields are Molecular Biology. (generated from OpenAlex topic counts and CAS ranking data)
The journal evaluates molecules, signalling pathways, receptors and other therapeutic targets and their potential as candidates for drug development. Articles in this journal focus on the molecular level and early preclinical studies. Articles should not include clinical information including specific drugs and clinical trials. The Editors welcome: Reviews covering novel disease targets at the molecular level and information on early preclinical studies and their implications for future drug development. Articles should not include clinical information including specific drugs and clinical trials. Original research papers reporting results of target selection and validation studies and basic mechanism of action studies for investigative and marketed drugs. The audience consists of scientists, managers and decision makers in the pharmaceutical industry, academic researchers working in the field of molecular medicine and others closely involved in R&D.
Source: LetPub
Research area (LetPub): Pharmacology & Pharmacy
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cytokine Signaling Pathways and InteractionsMedicine5.7%
- MicroRNA in disease regulationBiochemistry, Genetics and Molecular Biology4.7%
- PI3K/AKT/mTOR signaling in cancerBiochemistry, Genetics and Molecular Biology4.7%
- Peptidase Inhibition and AnalysisMedicine4.7%
- Ion channel regulation and functionBiochemistry, Genetics and Molecular Biology4.6%
- Epigenetics and DNA MethylationBiochemistry, Genetics and Molecular Biology4.3%
- Cell death mechanisms and regulationBiochemistry, Genetics and Molecular Biology4.3%
- Histone Deacetylase Inhibitors ResearchBiochemistry, Genetics and Molecular Biology4.2%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Pharmacology & Pharmacy | Zone 2 |
Top journal: noReview journal: yes
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 2 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Pharmacology & Pharmacy | Zone 2 |
Top journal: noReview journal: yes
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 5.27LetPub ·
- CiteScore 2026-06
- 8.6LetPub ·
- SJR 2026-06
- 1.38LetPub ·
- SNIP 2026-06
- 1.09LetPub ·
- h-index
- 78LetPub ·
- h-index
- 130OpenAlex ·
- i10-index
- 1,883OpenAlex ·
- 2-year mean citedness
- 3.9OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 11.48%LetPub ·
Volume
- Articles per year
- 44LetPub ·
Articles by year OpenAlex count · 2,712 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 84 | 30 | 29 |
| 2025 | 74 | 39 | 236 |
| 2024 | 86 | 33 | 686 |
| 2023 | 103 | 46 | 1,539 |
| 2022 | 82 | 35 | 1,614 |
| 2021 | 80 | 38 | 1,801 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
94 daysMedian, submission to acceptance · P25–P75 70 days – 135 days
- Acceptance to online
- median 9 days (108 articles)
- Submission to online
- median 104 days
- Sample
- 108 articles with submission and acceptance dates (174 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 4–8 weeksLetPub ·
- Average acceptance (community reports)
- ModerateLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
No source has fee information yet; check the journal's website.
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Policy excerpts from the journal's websiteOpen access
- Open access Open access
Overview Open journals Open Select Dove Medical Press F1000Research
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Taylor and Francis Ltd.
- Country or region
- ENGLAND
- Language
- English
- Frequency
- Monthly
- Founded
- 2001
- ISSN
- 1472-8222
- Electronic ISSN
- 1744-7631
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
FAQ
Frequently asked questions about Expert Opinion on Therapeutic Targets
What CAS zone is Expert Opinion on Therapeutic Targets in?
In the 2025 upgraded edition of the CAS Journal Ranking, Expert Opinion on Therapeutic Targets is in Zone 2 of Medicine, and in Zone 2 of the minor category Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Expert Opinion on Therapeutic Targets?
The latest impact factor listed by LetPub is 5.27; CiteScore 8.6, h-index 130.
How long does peer review take at Expert Opinion on Therapeutic Targets?
Based on the dates recorded on 108 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 94 days (interquartile range 70–135 days); authors report an average review time of 4–8 weeks; the community-reported acceptance is “Moderate”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Expert Opinion on Therapeutic Targets?
According to LetPub and DOAJ records, Expert Opinion on Therapeutic Targets is indexed in SCIE and Scopus.
Is Expert Opinion on Therapeutic Targets open access, and what is the APC?
Expert Opinion on Therapeutic Targets is a hybrid journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .